chevron_leftBack
As of 24 June 2026, Shanghai Allist Pharmaceuticals Co., Ltd. has a market cap of $6.21B USD, ranking #3190 globally and #566 in China.
It ranks #235 in the Healthcare sector, and #91 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$6.21BUSD
42.11B CNY
Enterprise Value
$5.75BUSD
38.95B CNY
Revenue (TTM)
$836.21MUSD
5.67B CNY
EBITDA (TTM)
$385.71MUSD
2.61B CNY
Net Income (TTM)
$355.94MUSD
2.41B CNY
EBITDA Margin
46%
Profit Margin
43%
PE Ratio
17.5
Forward PE
15.9
PS Ratio
7.4
PB Ratio
5.4
EV/EBITDA
14.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jinhao Du
open_in_new
Employees
1,989
Founded
2004
Website
allist.com.cn
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1% | -3.6% | -4% | -8.6% | -16% | 9.7% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
688578
上海艾力斯医药科技股份有限公司 Class A
ISIN: CNE100005XJ7
Shares Out.:
Shares Outstanding:
450.0M1
Shares Float:
218.458M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
92.60 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Shanghai Allist Pharmaceuticals Co., Ltd.
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company’s lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SSE: 600276
|
$53.79B
767%
364.89B CNY
|
44.9
|
|
SSE: 603259
|
$49.58B
699%
336.36B CNY
|
17.2
|
|
SHEK: 3692
|
$28.5B
359%
223.48B HKD
|
35.7
|
|
SHEK: 1801
|
$18.79B
203%
147.32B HKD
|
162.3
|
|
SSE: 688506
|
$16.49B
166%
111.89B CNY
|
-
|
|
SHEK: 9926
|
$16.0B
158%
125.46B HKD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
12K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
9K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
6K%
|
97.4
|
|
SIX: RO
|
$316.37B
5K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$284.33B
4K%
215.59B GBP
|
27.6
|
|
NYSE: MRK
|
$274.03B
4K%
|
15.1
|
chevron_leftBack